BioAscent opens new protein production facility
February 22, 2024Manufacturing and Production BioAscent, Pharmacy, facility, protein production
BioAscent has announced that it has opened its new state-of-the-art protein production facility in an event chaired by Professor Michael …
ViiV Healthcare shares interim data from phase 3 trial for injectable HIV treatment
February 21, 2024Research and Development Cabenuva, HIV, HIV/AIDS, ViiV Healthcare, clinical trial, injectables
ViiV Healthcare has announced results from an interim analysis of the phase 3 LATITUDE trial, which assessed Cabenuva (cabotegravir and …
Voyager Therapeutics shares data from preclinical programmes for Alzheimer’s treatment
February 21, 2024Research and Development Alzheimer's, Neurology, Voyager Therapeutics, preclinical
Voyager Therapeutics has announced new data from is two preclinical programmes targeting pathological tau for the treatment of Alzheimer’s disease …
Pfizer’s Velsipity approved by EC for ulcerative colitis treatment
February 20, 2024Medical Communications European Commission, Gastrointestinal tract, Pfizer, Velsipity, ulcerative colitis
Pfizer has announced that the European Commission (EC) has granted marketing authorisation for Velsipity (etrasimod) in the European Union (EU). …
argenx announces FDA acceptance of sBLA for Vyvgart Hytrulo for CIDP treatment
February 20, 2024Medical Communications CIDP, FDA, Neurology, Vyvgart Hytrulo, argenx, sBLA
argenx has announced that the US Food and Drug Administration (FDA) has accepted a supplemental Biologics License Application (sBLA) for …
AstraZeneca’s Tagrisso approved by FDA for lung cancer treatment
February 19, 2024Medical Communications AstraZeneca, Oncology, Tagrisso, lung cancer
AstraZeneca has announced that the US Food and Drug Administration (FDA) has approved Tagrisso for the treatment of adult patients …
Iovance’s Amtagvi gains FDA accelerated approval for melanoma treatment
February 19, 2024Medical Communications Iovance, Oncology, accelerated approval, melanoma
Iovance Biotherapeutics has announced that the US Food and Drug Administration (FDA) has approved Amtagvi (lifileucel) suspension for intravenous infusion …
Astellas and Kelonia Therapeutics enter agreement for development of immuno-oncology therapeutics
February 16, 2024Research and Development Astellas Pharma, Kelonia Therapeutics, Oncology, collaboration, immuno-oncology
Astellas Pharma and Kelonia Therapeutics have announced that Xyphos Biosciences (a wholly owned subsidiary of Astellas) and Kelonia have entered …
Freenome raises $254m funding for early cancer detection platform
February 16, 2024Research and Development Diagnostics, Freenome, Oncology, cancer detection, funding
Freenome has announced that it has raised $254m from new and existing investors, intended to be used for the advancement …
Domainex opens new Biology Centre of Excellence in Cambridge, UK
February 14, 2024Business Services Pharmacy, domainex, facility
Domainex has announced that it has opened a new Biology Centre of Excellence at the Unity Campus at Pampisford, Cambridge, …
FDA approves Ipsen’s Onivyde for pancreatic adenocarcinoma treatment
February 14, 2024Medical Communications FDA, Oncology, Onivyde, ipsen, pancreatic adenocarcinoma
Ipsen has announced that the US Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for …
EC approves Vertex’s Casgevy for sickle cell disease treatment
February 13, 2024Medical Communications Casgevy, European Commission, Haematology, Vertex pharmaceuticals, sickle cell disease
Vertex Pharmaceuticals has announced that the European Commission (EC) has granted conditional marketing authorisation to Casgevy (exagamglogene autotemcel), a CRISPR/Cas9 …
DelSiTech and Tolmar announce global license and development agreement
February 13, 2024Medical Communications DelSiTech, Pharmacy, Tolmar, collaboration
DelSiTech and Tolmar International have announced that they have entered into a global license and development agreement, following a previous …
J&J’s nipocalimab gains breakthrough therapy designation from FDA for HDFN treatment
February 12, 2024Medical Communications Breakthrough Therapy Designation, FDA, HDFN, J&J, Reproductive health
Johnson & Johnson (J&J) has announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) …
GSK gains FDA Fast Track designation for chronic hepatitis B treatment
February 12, 2024Medical Communications FDA, GSK, Hepatology, fast track designation, hepatitis B
GSK has announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for bepirovirsen, an investigational …
BioNTech and Autolus announce CAR T-cell therapy collaboration
February 9, 2024Research and Development Autolus, BioNTech, CAR T-cell, Oncology, collaboration
BioNTech and Autolus Therapeutics have announced that they have entered a strategic collaboration intended to further both companies’ autologous CAR …
Fresenius Medical Care gains FDA 501(k) clearance for haemodialysis system
February 9, 2024Medical Communications 501(k), FDA, Fresenius Medical Care, Nephrology, dialysis
Fresenius Medical Care has announced that it has received US Food and Drug Administration (FDA) 501(k) clearance for its 5008X …
Regenxbio announces positive data from trial for MPS II treatment
February 8, 2024Research and Development Hunter syndrome, MPS II, Neurology, Regenxbio, clinical trial
Regenxbio has announced topline results from the phase 1/2/3 CAMPSIITE trial of RGX-121 for the treatment of patients up to …
Tenax Therapeutics enrolls first patient in phase 3 trial for pulmonary hypertension treatment
February 8, 2024Research and Development Cardiology, Tenax Therapeutics, clinical trial, pulmonary hypertension
Tenax Therapeutics has announced that it has enrolled the first patient in its phase 3 LEVEL study, which aims to …
Jazz Pharmaceuticals enters agreement to acquire rights to KRAS inhibitor programme from Redx Pharma
February 7, 2024Business Services Pharmacy, RedX Pharma, acquisition, jazz pharmaceuticals
Jazz Pharmaceuticals and Redx Pharma have announced that the companies have signed a definitive agreement under which Jazz will acquire …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
